Theranos Inc., the startup with ambitions of disrupting the market for blood diagnostics, is currently using its proprietary technology on a single test out of the more than 200 it offers, Chief Executive Officer Elizabeth Holmes said in an interview.
The company says it will expand the use of its technology, which it has claimed can perform accurate tests with only few drops of blood, once the U.S. Food and Drug Administration clears it for more uses. Theranos started voluntarily limiting its technology to a single test this year, according to the company.
Read Full Article »